We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

19 hedge funds and large institutions have $177K invested in NeuBase Therapeutics, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

14% less funds holding

Funds holding: 22 → 19 (-3)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

48% less capital invested

Capital invested by funds: $340K → $177K (-$163K)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
19
Holders Change
-3
Holders Change %
-13.64%
% of All Funds
0.27%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
2
Increased
2
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$23.7K
2
CSS
Cubist Systematic Strategies
Connecticut
+$947
3
TRCT
Tower Research Capital (TRC)
New York
+$94

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$46.7K
2
Two Sigma Investments
Two Sigma Investments
New York
-$15.6K
3
KAS
Kestra Advisory Services
Texas
-$12.2K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$111
5
BlackRock
BlackRock
New York
-$62
Name Holding Trade Value Shares
Change 		Change in
Stake
DCM
1
DME Capital Management
New York
$61.3K +$103K +136,350 New
Renaissance Technologies
2
Renaissance Technologies
New York
$40K +$23.7K +31,262 +55%
Point72 Asset Management
3
Point72 Asset Management
Connecticut
$28.1K – – –
CMU
4
Carnegie Mellon University
Pennsylvania
$21.1K – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$8.54K – – –
PCM
6
Prelude Capital Management
New York
$7K – – –
Geode Capital Management
7
Geode Capital Management
Massachusetts
$6.84K – – –
UBS Group
8
UBS Group
Switzerland
$1.82K -$46.7K -61,668 -94%
TRCT
9
Tower Research Capital (TRC)
New York
$1.16K +$94 +124 +5%
CSS
10
Cubist Systematic Strategies
Connecticut
$563 +$947 +1,251 New
Bank of America
11
Bank of America
North Carolina
$361 – – –
First Manhattan
12
First Manhattan
New York
$158 – – –
Wells Fargo
13
Wells Fargo
California
$35 – – –
Osaic Holdings
14
Osaic Holdings
Arizona
$10 – – –
PNC Financial Services Group
15
PNC Financial Services Group
Pennsylvania
$9 – – –
NFSG
16
Newbridge Financial Services Group
Florida
$5 – – –
Morgan Stanley
17
Morgan Stanley
New York
$4 -$7 -9 -50%
Two Sigma Investments
18
Two Sigma Investments
New York
– -$15.6K -21,083 Closed
KAS
19
Kestra Advisory Services
Texas
– -$12.2K -16,476 Closed
Royal Bank of Canada
20
Royal Bank of Canada
Ontario, Canada
– -$111 -147 -49%
BlackRock
21
BlackRock
New York
– -$62 -84 Closed
GWMIA
22
Global Wealth Management Investment Advisory
Florida
– -$9 -12 Closed

NBSE Hedge Fund Activity: Q1 2024 in Review

19 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q1 2024, worth a combined $177K — down 48% from $340K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of NBSE and 2 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 2 added.

The largest buyer was Renaissance Technologies, adding an estimated $23.7K. The largest seller was UBS Group, cutting an estimated $46.7K.

  • 19 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q1 2024, down from 22 in Q4 2023.
  • Funds reported $177K of NeuBase Therapeutics, Inc. Common Stock stock for Q1 2024, down 48% quarter-over-quarter.
  • 2 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q1 2024 and 4 closed out, a net change of -2 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q1 2024 was Renaissance Technologies, an estimated $23.7K added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q1 2024 was UBS Group, an estimated $46.7K sold.

Based on aggregated 13F filings for Q1 2024.